Načítá se...
Novel Therapeutic Agents in Waldenström’s Macroglobulinemia
Within the past few years, major advances in the preclinical and clinical testing of novel therapeutic agents have occurred in Waldenström’s macroglobulinemia (WM). These include agents that target the PI3K/Akt/mTOR pathway, PKC pathways, NF-kB signaling pathway, as well as tyrosine kinases and hist...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2009
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3133646/ https://ncbi.nlm.nih.gov/pubmed/19362982 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3816/CLM.2009.n.022 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|